121 cases of adverse drug reaction of secondline antituberculosis drugs
Author:
Affiliation:

Clc Number:

R969.3

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    ObjectiveTo explore the characteristics of adverse drug reaction (ADR) of secondline antituberculosis(TB) drugs.MethodsCase history of patients with ADR due to use of secondline antiTB drugs was selected from the ADR report summary table of a hospital in 2017, the occurrence of ADR, types of ADR, patients’ organ systems involved in ADR and the main clinical manifestations as well as prognostic data were analyzed.ResultsOf 121 patients with ADR due to secondline antiTB drugs, 59.50% (n=72) were males, 57.85%(n=70) were aged more than 60 years. The main dosage which inducing ADR is injection type(n=80, 66.12%), the main drugs were moxifloxacin (n=38, 31.40%) and levofloxacin (n=29, 23.96%). The main organ system involved in ADR was systemic (69/128, 53.91%), followed by central and peripheral nervous system (22/128, 17.19%). 9 patients(7.44%) were with severe ADR, 118 patients(97.52%)were recovered and improved.ConclusionADR due to use of secondline antiTB drugs often occurs in elderly patients, the main damage are systemic and peripheral nervous system damage due to use of quinolones. In the course of diagnosis and treatment, the highrisk population and the main therapeutic drugs should be monitored and performed active intervention, and the corresponding measures should be taken

    Reference
    Related
Get Citation

高利臣,等.121例二线抗结核药品不良反应分析[J].中国感染控制杂志英文版,2018,17(12):1070-1074. DOI:10.3969/j. issn.1671-9638.2018.12.008.
GAO Lichen, et al.121 cases of adverse drug reaction of secondline antituberculosis drugs[J]. Chin J Infect Control, 2018,17(12):1070-1074. DOI:10.3969/j. issn.1671-9638.2018.12.008.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:May 17,2018
  • Revised:July 06,2018
  • Adopted:
  • Online: December 28,2018
  • Published: